A
APREA THERAPEUTICS INC
NASDAQ: APRE (Aprea Therapeutics, Inc.)
Last update: 17 hours ago0.715
-0.06 (-8.31%)
| Previous Close | 0.780 |
| Open | 0.783 |
| Volume | 76,252 |
| Avg. Volume (3M) | 377,908 |
| Market Cap | 8,853,685 |
| Price / Book | 0.230 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,514.78% |
| Diluted EPS (TTM) | -2.34 |
| Quarterly Revenue Growth (YOY) | -57.30% |
| Current Ratio (MRQ) | 5.90 |
| Operating Cash Flow (TTM) | -13.25 M |
| Levered Free Cash Flow (TTM) | -8.46 M |
| Return on Assets (TTM) | -35.70% |
| Return on Equity (TTM) | -59.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Aprea Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.3
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.30 |
|
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.90% |
| % Held by Institutions | 40.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aigh Capital Management Llc | 31 Mar 2026 | 1,015,541 |
| Vestal Point Capital, Lp | 31 Mar 2026 | 350,000 |
| Sphera Funds Management Ltd. | 31 Mar 2026 | 270,000 |
| Hightower Advisors, Llc | 31 Mar 2026 | 13,864 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BIZZARI JEAN-PIERRE | 0.729 | - | 3,135 | 2,285 |
| DUEY MARC | 0.729 | - | 3,135 | 2,285 |
| GRISSINGER MICHAEL | 0.729 | - | 3,135 | 2,285 |
| GRUIA GABRIELA | 0.729 | - | 3,135 | 2,285 |
| HENNEMAN JOHN B III | 0.729 | - | 3,135 | 2,285 |
| PAMUKCU RIFAT | 0.729 | - | 3,135 | 2,285 |
| PETERS RICHARD | 0.729 | - | 3,135 | 2,285 |
| SEIZINGER BERND R. | 0.729 | - | 3,135 | 2,285 |
| Aggregate Net Quantity | 25,080 | |||
| Aggregate Net Value ($) | 18,283 | |||
| Aggregate Avg. Buy ($) | 0.729 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SEIZINGER BERND R. | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| PAMUKCU RIFAT | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| DUEY MARC | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| BIZZARI JEAN-PIERRE | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| HENNEMAN JOHN B III | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| PETERS RICHARD | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| GRUIA GABRIELA | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
| GRISSINGER MICHAEL | Director | 16 Jun 2026 | Acquired (+) | 3,135 | 0.729 | 2,285 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |